Design of a robust infrastructure to monitor the safety of the pandemic A(H1N1) 2009 vaccination program in Taiwan

Vaccine

Volumn 28, Issue 44, 2010, Pages 7161-7166

  Huang, Wan Ting ^a   Chen, Wen Wen ^b   Yang, Hsu Wen ^a   Chen, Wan Chin ^a   Chao, Yen Nan ^a   Huang, Yu Wen ^c,d   Chuang, Jen Hsiang ^a   Kuo, Hsu Sung ^a  

^a CENTER FOR DISEASE CONTROL   (Taiwan)

^b Taiwan Drug Relief Foundation   (Taiwan)

^c Executive Yuan   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Influenza vaccines; Pandemic H1N1; Postmarketing surveillance

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; BELL PALSY; DEMYELINATING DISEASE; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENCEPHALITIS; GOVERNMENT; GUILLAIN BARRE SYNDROME; HEALTH PROGRAM; HUMAN; IMMUNE THROMBOCYTOPENIA; INFLUENZA A (H1N1); INFLUENZA VACCINATION; MASS IMMUNIZATION; MYELITIS; NEWBORN DEATH; PANDEMIC INFLUENZA; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT; SPONTANEOUS ABORTION; STILLBIRTH; TAIWAN; THROMBOCYTOPENIA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MASS VACCINATION; PRODUCT SURVEILLANCE, POSTMARKETING; TAIWAN;

EID: 77957762373     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.069     Document Type: Article

References (30)

1. World Health Organization. Statement to the press by WHO Director-General Dr Margaret Chan; 11 June 2009. World now at the start of 2009 influenza pandemic. Available at (accessed August 9, 2010). http://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/index.html.
2. Bureau of National Health Insurance. National Health Insurance in Taiwan; 2009. (accessed August 9, 2010). http://www.nhi.gov.tw/webdata/AttachFiles/Attach_13787_1_NationalHealthInsuranceinTaiwan2009.pdf.
3. Black S., Eskola J., Siegrist C.-A., Halsey N., MacDonald N., Law B., et al. Importance of background rates of disease in assessment of vaccine safety during mass immunization with pandemic H1N1 influenza vaccines. Lancet 2009, 374(9707):2115-2122.
4. Greene S.K., Kulldorff M., Lewis E.M., Li R., Yin R., Weintraub E.S., et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. Am J Epidemiol 2010, 171(2):177-188.
5. Juurlink D.N., Stukel T.A., Kwong J., Kopp A., McGeer A., Upshur R.E., et al. Guillain-Barré syndrome after influenza vaccination in adults: a population-based study. Arch Intern Med 2006, 166(20):2217-2221.
6. Schonberger L.B., Bregman D.J., Sullivan-Bolyai J.E., Keenlyside R.A., Ziegler D.W., Retailliau H.F., et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979, 110(2):105-123.
7. Haber P., DeStefano F., Angulo F.J., Iskander J., Shadomy S.V., Weintraub E., et al. Guillain-Barré syndrome following influenza vaccination. JAMA 2004, 292(20):2478-2481.
8. Vellozzi C., Burwen D.R., Dobardzic A., Ball R., Walton K., Haber P. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine 2009, 27(15):2114-2120.
9. McMahon A.W., Iskander J., Haber P., Chang S., Woo E.J., Braun M.M., et al. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the Vaccine Adverse Event Reporting System, 1990-2003. Pediatrics 2005, 115(2):453-460.
10. Zhou W., Pool V., DeStefano F., Iskander J.K., Haber P., Chen R.T. A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001. Pharmacoepidemiol Drug Saf 2004, 13(8):505-510. VAERS Working Group.
11. Stowe J., Andrews N., Wise L., Miller E. Bell's palsy and parenteral inactivated influenza vaccine. Hum Vaccin 2006, 2(3):110-112.
12. Bohlke K., Davis R.L., Marcy S.M., Braun M.M., DeStefano F., Black S.B., et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003, 112(4):815-820.
13. Huang W.T., Chuang J.H., Kuo S.H. Monitoring the safety of pandemic H1N1 vaccine. Lancet 2010, 375(9721):1164.
14. Bonhoeffer J., Bentsi-Enchill A., Chen R.T., Fisher M.C., Gold M.S., Hartman K., et al. Guidelines for collection, analysis and presentation of vaccine safety in surveillance systems. Vaccine 2009, 27(16):2289-2297.
15. Department of Health, Executive Yuan. Vaccine Injury Compensation Program. Available at (accessed August 9, 2010). http://www.cdc.gov.tw/public/Data/7121816161871.doc.
16. Department of Health, Executive Yuan. National Reporting System of Adverse Drug Reactions in Taiwan [Chinese]. Available at (accessed August 9, 2010). http://adr.doh.gov.tw/.
17. Medical Dictionary for Regulatory Activities. Maintenance and Support Services Organization. Available at (accessed August 9, 2010). http://www.meddramsso.com/.
18. The Brighton Collaboration. Available at (accessed August 9, 2010). https://brightoncollaboration.org/public/.
19. Silver R.M., Varner M.W., Reddy U., Goldenberg R., Pinar H., Conway D., et al. Work-up of stillbirth: a review of the evidence. Am J Obstet Gynecol 2007, 196(5):433-444.
20. Verstraeten T., DeStefano F., Chen R.T., Miller E. Vaccine safety surveillance using large linked databases: opportunities, hazards and proposed guidelines. Expert Rev Vaccines 2003, 2(1):21-29.
21. Munoz F.M., Greisinger A.J., Wehmanen O.A., Mouzoon M.E., Hoyle J.C., Smith F.A., et al. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol 2005, 192(4):1098-1106.
22. DeStefano F. The Vaccine Safety Datalink project. Pharmacoepidemiol Drug Saf 2001, 10(5):403-406. for the Vaccine Safety Datalink Research Group.
23. Lieu T.A., Kulldorff M., Davis R.L., Lewis E.M., Weintraub E., Yih K., et al. Real-time vaccine safety surveillance for the early detection of adverse events. Med Care 2007, 45(10):S89-S95.
24. Whitaker H.J., Farrington C.P., Spiessens B., Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med 2006, 25(10):1768-1797.
25. Kulldorff M, Davis RL, Kolczak M, Lewis E, Lieu T, Platt R. A maximized sequential probability ratio test for drug and vaccine safety surveillance. Available at (accessed August 9, 2010). http://www.populationmedicine.org/content/docs/maxSPRTsubm.pdf.
26. Chiu PJ, Huang WT, Huang SE, Chih YC, Chen CH. Program errors in Taiwan's mass immunizations against pandemic A/H1N1. Taiwan Epidemiol Bull 2010;26(15):268-75. Available at (accessed August 9, 2010). http://teb.cdc.gov.tw/content.asp%3FCuItem=15522%26mp=181.
27. Central Epidemic Command Center. The adverse event following pandemic A (H1N1) 2009 vaccination data [Chinese]. Available at (accessed August 9, 2010). http://www.h1n1.gov.tw/lp.asp%3FctNode=3851%26CtUnit=858%26BaseDSD=7%26mp=170.
28. Department of Health, Executive Yuan. Total claims of vaccine injury compensation between 1998 and 2009, by vaccine. Available at (accessed August 9, 2010). http://www.cdc.gov.tw/public/Data/01411552571.pdf.
29. Department of Health, Executive Yuan. The adverse drug reaction reporting form. Available at (accessed August 9, 2010). http://adr.doh.gov.tw/db/download/9.doc.
30. Varricchio F., Iskander J., DeStefano F., Ball R., Pless R., et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004, 23(4):287-294.